

El Simpson

List of Publications by Citations

Source: <https://exaly.com/author-pdf/6603586/el-simpson-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

165
papers

11,200
citations

51
h-index

104
g-index

198
ext. papers

15,113
ext. citations

5.2
avg, IF

6.41
L-index

#	Paper	IF	Citations
165	Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis. <i>New England Journal of Medicine</i> , 2016 , 375, 2335-2348	59.2	936
164	Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. <i>New England Journal of Medicine</i> , 2014 , 371, 130-9	59.2	841
163	Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies. <i>Journal of the American Academy of Dermatology</i> , 2014 , 71, 116-32	4.5	670
162	Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis. <i>Journal of the American Academy of Dermatology</i> , 2014 , 70, 338-51	4.5	592
161	Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. <i>Lancet, The</i> , 2017 , 389, 2287-2303	4.0	559
160	Guidelines of care for the management of atopic dermatitis: section 3. Management and treatment with phototherapy and systemic agents. <i>Journal of the American Academy of Dermatology</i> , 2014 , 71, 327-45	4.5	489
159	Emollient enhancement of the skin barrier from birth offers effective atopic dermatitis prevention. <i>Journal of Allergy and Clinical Immunology</i> , 2014 , 134, 818-23	11.5	461
158	Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial. <i>Lancet, The</i> , 2016 , 387, 40-52	4.0	360
157	Guidelines of care for the management of atopic dermatitis: Section 4. Prevention of disease flares and use of adjunctive therapies and approaches. <i>Journal of the American Academy of Dermatology</i> , 2014 , 71, 1218-33	4.5	197
156	Efficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical corticosteroids: A randomized, placebo-controlled phase II trial (TREBLE). <i>Journal of the American Academy of Dermatology</i> , 2018 , 78, 863-871.e11	4.5	185
155	Patient burden and quality of life in atopic dermatitis in US adults: A population-based cross-sectional study. <i>Annals of Allergy, Asthma and Immunology</i> , 2018 , 121, 340-347	3.2	183
154	The Harmonising Outcome Measures for Eczema (HOME) statement to assess clinical signs of atopic eczema in trials. <i>Journal of Allergy and Clinical Immunology</i> , 2014 , 134, 800-7	11.5	183
153	Association between severe eczema in children and multiple comorbid conditions and increased healthcare utilization. <i>Pediatric Allergy and Immunology</i> , 2013 , 24, 476-86	4.2	183
152	Patient burden of moderate to severe atopic dermatitis (AD): Insights from a phase 2b clinical trial of dupilumab in adults. <i>Journal of the American Academy of Dermatology</i> , 2016 , 74, 491-8	4.5	180
151	Baricitinib in adult patients with moderate-to-severe atopic dermatitis: A phase 2 parallel, double-blinded, randomized placebo-controlled multiple-dose study. <i>Journal of the American Academy of Dermatology</i> , 2019 , 80, 913-921.e9	4.5	176
150	Conjunctivitis in dupilumab clinical trials. <i>British Journal of Dermatology</i> , 2019 , 181, 459-473	4	147
149	Efficacy and Safety of Dupilumab in Adolescents With Uncontrolled Moderate to Severe Atopic Dermatitis: A Phase 3 Randomized Clinical Trial. <i>JAMA Dermatology</i> , 2020 , 156, 44-56	5.1	146

148	Associations of childhood eczema severity: a US population-based study. <i>Dermatitis</i> , 2014 , 25, 107-14	2.6	143
147	A pilot study of emollient therapy for the primary prevention of atopic dermatitis. <i>Journal of the American Academy of Dermatology</i> , 2010 , 63, 587-93	4.5	138
146	Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials. <i>British Journal of Dermatology</i> , 2020 , 183, 242-255	4	137
145	The Harmonizing Outcome Measures for Eczema (HOME) roadmap: a methodological framework to develop core sets of outcome measurements in dermatology. <i>Journal of Investigative Dermatology</i> , 2015 , 135, 24-30	4.3	135
144	Persistence of atopic dermatitis (AD): A systematic review and meta-analysis. <i>Journal of the American Academy of Dermatology</i> , 2016 , 75, 681-687.e11	4.5	129
143	Atopic Dermatitis in America Study: A Cross-Sectional Study Examining the Prevalence and Disease Burden of Atopic Dermatitis in the US Adult Population. <i>Journal of Investigative Dermatology</i> , 2019 , 139, 583-590	4.3	126
142	Efficacy and Safety of Lebrikizumab, a High-Affinity Interleukin 13 Inhibitor, in Adults With Moderate to Severe Atopic Dermatitis: A Phase 2b Randomized Clinical Trial. <i>JAMA Dermatology</i> , 2020 , 156, 411-420	5.1	118
141	What the Eczema Area and Severity Index score tells us about the severity of atopic dermatitis: an interpretability study. <i>British Journal of Dermatology</i> , 2015 , 172, 1353-7	4	116
140	Atopic dermatitis: a review of topical treatment options. <i>Current Medical Research and Opinion</i> , 2010 , 26, 633-40	2.5	110
139	Dupilumab therapy provides clinically meaningful improvement in patient-reported outcomes (PROs): A phase IIb, randomized, placebo-controlled, clinical trial in adult patients with moderate to severe atopic dermatitis (AD). <i>Journal of the American Academy of Dermatology</i> , 2016 , 75, 506-515	4.5	104
138	A systematic review of Investigator Global Assessment (IGA) in atopic dermatitis (AD) trials: Many options, no standards. <i>Journal of the American Academy of Dermatology</i> , 2016 , 74, 288-94	4.5	103
137	When does atopic dermatitis warrant systemic therapy? Recommendations from an expert panel of the International Eczema Council. <i>Journal of the American Academy of Dermatology</i> , 2017 , 77, 623-633	4.5	103
136	Efficacy and Safety of Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial. <i>JAMA Dermatology</i> , 2020 , 156, 863-873	5.1	102
135	Patient-Oriented Eczema Measure (POEM), a core instrument to measure symptoms in clinical trials: a Harmonising Outcome Measures for Eczema (HOME) statement. <i>British Journal of Dermatology</i> , 2017 , 176, 979-984	4	99
134	Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. <i>Lancet, The</i> , 2020 , 396, 255-266	4.0	99
133	Report from the fourth international consensus meeting to harmonize core outcome measures for atopic eczema/dermatitis clinical trials (HOME initiative). <i>British Journal of Dermatology</i> , 2016 , 175, 69-79	4	90
132	Assessment of atopic dermatitis using self-report and caregiver report: a multicentre validation study. <i>British Journal of Dermatology</i> , 2015 , 173, 1400-4	4	84
131	Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2). <i>British Journal of Dermatology</i> , 2021 , 184, 437-449	4	84

130	Effect of 2 Psoriasis Treatments on Vascular Inflammation and Novel Inflammatory Cardiovascular Biomarkers: A Randomized Placebo-Controlled Trial. <i>Circulation: Cardiovascular Imaging</i> , 2018 , 11, e007394	3.9	81
129	Major Comorbidities of Atopic Dermatitis: Beyond Allergic Disorders. <i>American Journal of Clinical Dermatology</i> , 2018 , 19, 821-838	7.1	76
128	Symptoms and diagnosis of anxiety and depression in atopic dermatitis in U.S. adults. <i>British Journal of Dermatology</i> , 2019 , 181, 554-565	4	74
127	Report from the third international consensus meeting to harmonise core outcome measures for atopic eczema/dermatitis clinical trials (HOME). <i>British Journal of Dermatology</i> , 2014 , 171, 1318-25	4	74
126	Daily emollient during infancy for prevention of eczema: the BEEP randomised controlled trial. <i>Lancet, The</i> , 2020 , 395, 962-972	4.0	72
125	Efficacy and Safety of Baricitinib Combined With Topical Corticosteroids for Treatment of Moderate to Severe Atopic Dermatitis: A Randomized Clinical Trial. <i>JAMA Dermatology</i> , 2020 , 156, 1333-1343	5.1	67
124	Emollient use alters skin barrier and microbes in infants at risk for developing atopic dermatitis. <i>PLoS ONE</i> , 2018 , 13, e0192443	3.7	66
123	Infections in Dupilumab Clinical Trials in Atopic Dermatitis: A Comprehensive Pooled Analysis. <i>American Journal of Clinical Dermatology</i> , 2019 , 20, 443-456	7.1	65
122	Association of atopic dermatitis with allergic, autoimmune, and cardiovascular comorbidities in US adults. <i>Annals of Allergy, Asthma and Immunology</i> , 2018 , 121, 604-612.e3	3.2	65
121	Efficacy and safety of dupilumab monotherapy in adults with moderate-to-severe atopic dermatitis: a pooled analysis of two phase 3 randomized trials (LIBERTY AD SOLO 1 and LIBERTY AD SOLO 2). <i>Journal of Dermatological Science</i> , 2019 , 94, 266-275	4.3	59
120	Improvement of skin barrier function in atopic dermatitis patients with a new moisturizer containing a ceramide precursor. <i>Journal of Dermatological Treatment</i> , 2013 , 24, 122-5	2.8	58
119	Dupilumab does not affect correlates of vaccine-induced immunity: A randomized, placebo-controlled trial in adults with moderate-to-severe atopic dermatitis. <i>Journal of the American Academy of Dermatology</i> , 2019 , 80, 158-167.e1	4.5	57
118	Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials. <i>Lancet, The</i> , 2021 , 397, 2151-2168	4.0	55
117	Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis. <i>New England Journal of Medicine</i> , 2021 , 384, 1101-1112	59.2	54
116	Effectiveness and cost-effectiveness of daily all-over-body application of emollient during the first year of life for preventing atopic eczema in high-risk children (The BEEP trial): protocol for a randomised controlled trial. <i>Trials</i> , 2017 , 18, 343	2.8	50
115	Pain Is a Common and Burdensome Symptom of Atopic Dermatitis in United States Adults. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2019 , 7, 2699-2706.e7	5.4	50
114	Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial. <i>JAMA Dermatology</i> , 2021 , 157, 1047-1055	5.1	48
113	Association of Inadequately Controlled Disease and Disease Severity With Patient-Reported Disease Burden in Adults With Atopic Dermatitis. <i>JAMA Dermatology</i> , 2018 , 154, 903-912	5.1	45

112	Atopic dermatitis. <i>Medical Clinics of North America</i> , 2006 , 90, 149-67, ix	7	44
111	Altered composition of epidermal lipids correlates with <i>Staphylococcus aureus</i> colonization status in atopic dermatitis. <i>British Journal of Dermatology</i> , 2017 , 177, e125-e127	4	43
110	Efficacy and Safety of Multiple Dupilumab Dose Regimens After Initial Successful Treatment in Patients With Atopic Dermatitis: A Randomized Clinical Trial. <i>JAMA Dermatology</i> , 2020 , 156, 131-143	5.1	43
109	Report from the fifth international consensus meeting to harmonize core outcome measures for atopic eczema/dermatitis clinical trials (HOME initiative). <i>British Journal of Dermatology</i> , 2018 , 178, e332-e341	4	42
108	Laboratory safety of dupilumab in moderate-to-severe atopic dermatitis: results from three phase III trials (LIBERTY AD SOLO 1, LIBERTY AD SOLO 2, LIBERTY AD CHRONOS). <i>British Journal of Dermatology</i> , 2020 , 182, 1120-1135	4	42
107	How should an incident case of atopic dermatitis be defined? A systematic review of primary prevention studies. <i>Journal of Allergy and Clinical Immunology</i> , 2012 , 130, 137-44	11.5	39
106	Comorbidity in Atopic Dermatitis. <i>Current Dermatology Reports</i> , 2012 , 1, 29-38	1.5	39
105	Dupilumab treatment results in early and sustained improvements in itch in adolescents and adults with moderate to severe atopic dermatitis: Analysis of the randomized phase 3 studies SOLO 1 and SOLO 2, AD ADOL, and CHRONOS. <i>Journal of the American Academy of Dermatology</i> , 2020 , 82, 1328-1336	4.5	36
104	A Randomized Placebo-Controlled Trial of Secukinumab on Aortic Vascular Inflammation in Moderate-to-Severe Plaque Psoriasis (VIP-S). <i>Journal of Investigative Dermatology</i> , 2020 , 140, 1784-1793.e2	4.3	36
103	Pooled safety analysis of baricitinib in adult patients with atopic dermatitis from 8 randomized clinical trials. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021 , 35, 476-485	4.6	35
102	Inadequate response to ustekinumab in atopic dermatitis - a report of two patients. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2016 , 30, 522-3	4.6	34
101	Prevalence and morphology of hand eczema in patients with atopic dermatitis. <i>Dermatitis</i> , 2006 , 17, 123-26	7	33
100	Prevalence of botanical extract allergy in patients with contact dermatitis. <i>Dermatitis</i> , 2004 , 15, 67-72	2.6	33
99	Dupilumab Improves General Health-Related Quality-of-Life in Patients with Moderate-to-Severe Atopic Dermatitis: Pooled Results from Two Randomized, Controlled Phase 3 Clinical Trials. <i>Dermatology and Therapy</i> , 2017 , 7, 243-248	4	29
98	Distribution of atopic dermatitis lesions in United States adults. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019 , 33, 1341-1348	4.6	29
97	Atopic dermatitis in the pediatric population: A cross-sectional, international epidemiologic study. <i>Annals of Allergy, Asthma and Immunology</i> , 2021 , 126, 417-428.e2	3.2	28
96	Strategies used for measuring long-term control in atopic dermatitis trials: A systematic review. <i>Journal of the American Academy of Dermatology</i> , 2016 , 75, 1038-1044	4.5	27
95	Content and construct validity, predictors, and distribution of self-reported atopic dermatitis severity in US adults. <i>Annals of Allergy, Asthma and Immunology</i> , 2018 , 121, 729-734.e4	3.2	27

94	Severity strata for five patient-reported outcomes in adults with atopic dermatitis. <i>British Journal of Dermatology</i> , 2018 , 178, 925-930	4	25
93	Dust mite avoidance for the primary prevention of atopic dermatitis: A systematic review and meta-analysis. <i>Pediatric Allergy and Immunology</i> , 2015 , 26, 646-54	4.2	25
92	Dupilumab improves patient-reported symptoms of atopic dermatitis, symptoms of anxiety and depression, and health-related quality of life in moderate-to-severe atopic dermatitis: analysis of pooled data from the randomized trials SOLO 1 and SOLO 2. <i>Journal of Dermatological Treatment</i> , 2020 , 31, 606-614	2.8	25
91	A new body moisturizer increases skin hydration and improves atopic dermatitis symptoms among children and adults. <i>Journal of Drugs in Dermatology</i> , 2011 , 10, 744-9	2.2	25
90	Navigating the landscape of core outcome set development in dermatology. <i>Journal of the American Academy of Dermatology</i> , 2019 , 81, 297-305	4.5	24
89	Clinically Meaningful Responses to Dupilumab in Adolescents with Uncontrolled Moderate-to-Severe Atopic Dermatitis: Post-hoc Analyses From a Randomized Clinical Trial. <i>American Journal of Clinical Dermatology</i> , 2020 , 21, 119-131	7.1	24
88	Dupilumab provides important clinical benefits to patients with atopic dermatitis who do not achieve clear or almost clear skin according to the Investigator's Global Assessment: a pooled analysis of data from two phase III trials. <i>British Journal of Dermatology</i> , 2019 , 181, 80-87	4	22
87	Economic Evaluation of Dupilumab for the Treatment of Moderate-to-Severe Atopic Dermatitis in Adults. <i>Dermatology and Therapy</i> , 2017 , 7, 493-505	4	22
86	The socioeconomics of atopic dermatitis. <i>Annals of Allergy, Asthma and Immunology</i> , 2019 , 122, 360-366	3.2	22
85	Safety and tolerability of a body wash and moisturizer when applied to infants and toddlers with a history of atopic dermatitis: results from an open-label study. <i>Pediatric Dermatology</i> , 2012 , 29, 590-7	1.9	21
84	A comparison of five ways to measure atopic dermatitis severity in adults. <i>British Journal of Dermatology</i> , 2020 , 182, e26-e26	4	20
83	Quality of Life and Disease Impact of Atopic Dermatitis and Psoriasis on Children and Their Families. <i>Children</i> , 2019 , 6,	2.8	18
82	Recommended core outcome instruments for health-related quality of life, long-term control and itch intensity in atopic eczema trials: results of the HOME VII consensus meeting. <i>British Journal of Dermatology</i> , 2021 , 185, 139-146	4	18
81	Validation of the Atopic Dermatitis Control Tool (ADCT [®]) using a longitudinal survey of biologic-treated patients with atopic dermatitis. <i>BMC Dermatology</i> , 2019 , 19, 15	2.1	17
80	Current issues in atopic comorbidities and preventing the atopic march. <i>Seminars in Cutaneous Medicine and Surgery</i> , 2012 , 31, S6-9	1.4	17
79	Atopic dermatitis: Role of the skin barrier, environment, microbiome, and therapeutic agents. <i>Journal of Dermatological Science</i> , 2021 , 102, 142-157	4.3	17
78	Trim32 Deficiency Enhances Th2 Immunity and Predisposes to Features of Atopic Dermatitis. <i>Journal of Investigative Dermatology</i> , 2017 , 137, 359-366	4.3	16
77	Transcutaneous yellow fever vaccination of subjects with or without atopic dermatitis. <i>Journal of Allergy and Clinical Immunology</i> , 2014 , 133, 439-47	11.5	16

76	Standardized reporting of the Eczema Area and Severity Index (EASI) and the Patient-Oriented Eczema Measure (POEM): a recommendation by the Harmonising Outcome Measures for Eczema (HOME) Initiative. <i>British Journal of Dermatology</i> , 2018 , 179, 540-541	4	15
75	Evaluating patient-perceived control of atopic dermatitis: design, validation, and scoring of the Atopic Dermatitis Control Tool (ADCT). <i>Current Medical Research and Opinion</i> , 2020 , 36, 367-376	2.5	15
74	Measurement Properties of the Hospital Anxiety and Depression Scale Used in Atopic Dermatitis in Adults. <i>Journal of Investigative Dermatology</i> , 2019 , 139, 1388-1391	4.3	14
73	Validation of five patient-reported outcomes for atopic dermatitis severity in adults. <i>British Journal of Dermatology</i> , 2020 , 182, 104-111	4	14
72	Conceptual Model to Illustrate the Symptom Experience and Humanistic Burden Associated With Atopic Dermatitis in Adults and Adolescents. <i>Dermatitis</i> , 2019 , 30, 247-254	2.6	14
71	Crisaborole Ointment Improves Quality of Life of Patients with Mild to Moderate Atopic Dermatitis and Their Families. <i>Dermatology and Therapy</i> , 2018 , 8, 605-619	4	14
70	Alopecia areata in 2 patients treated with dupilumab: New onset and worsening. <i>JAAD Case Reports</i> , 2019 , 5, 643-645	1.4	13
69	Responder Threshold for Patient-Oriented Eczema Measure (POEM) and Children's Dermatology Life Quality Index (CDLQI) in Adolescents with Atopic Dermatitis. <i>Dermatology and Therapy</i> , 2019 , 9, 799-805	4	13
68	Atopic dermatitis prevention. <i>Dermatologic Therapy</i> , 2006 , 19, 108-117	2.2	13
67	A cross-sectional survey of complementary and alternative medicine use in patients with atopic dermatitis. <i>Dermatitis</i> , 2003 , 14, 144-7	2.6	13
66	Mutations in POGlut1 in Galli-Galli/Dowling-Degos disease. <i>British Journal of Dermatology</i> , 2017 , 176, 270-274	4	12
65	Long-term Efficacy of Baricitinib in Adults With Moderate to Severe Atopic Dermatitis Who Were Treatment Responders or Partial Responders: An Extension Study of 2 Randomized Clinical Trials. <i>JAMA Dermatology</i> , 2021 , 157, 691-699	5.1	12
64	Validation of a novel smartphone application-enabled, patient-operated skin barrier device. <i>Skin Research and Technology</i> , 2019 , 25, 612-617	1.9	11
63	Measuring atopic eczema symptoms in clinical practice: The first consensus statement from the Harmonising Outcome Measures for Eczema in clinical practice initiative. <i>Journal of the American Academy of Dermatology</i> , 2020 , 82, 1181-1186	4.5	11
62	Developing drugs for treatment of atopic dermatitis in children (8 months to . <i>Pediatric Dermatology</i> , 2018 , 35, 303-322	1.9	10
61	Validation and Interpretation of Short Form 12 and Comparison with Dermatology Life Quality Index in Atopic Dermatitis in Adults. <i>Journal of Investigative Dermatology</i> , 2019 , 139, 2090-2097.e3	4.3	10
60	Topical corticosteroid withdrawal in a pediatric patient. <i>JAAD Case Reports</i> , 2017 , 3, 420-421	1.4	10
59	A Community-based Assessment of Skin Care, Allergies, and Eczema (CASCADE): an atopic dermatitis primary prevention study using emollients-protocol for a randomized controlled trial. <i>Trials</i> , 2020 , 21, 243	2.8	9

58	New and Emerging Biologics for Atopic Dermatitis. <i>American Journal of Clinical Dermatology</i> , 2020 , 21, 457-465	7.1	9
57	Extended Safety Analysis of Baricitinib 2 mg in Adult Patients with Atopic Dermatitis: An Integrated Analysis from Eight Randomized Clinical Trials. <i>American Journal of Clinical Dermatology</i> , 2021 , 22, 395-405	7.1	9
56	Skin care interventions in infants for preventing eczema and food allergy. <i>The Cochrane Library</i> , 2021 , 2, CD013534	5.2	9
55	The Burden of Childhood Atopic Dermatitis in the Primary Care Setting: A Report from the Meta-LARC Consortium. <i>Journal of the American Board of Family Medicine</i> , 2019 , 32, 191-200	1.6	8
54	Severity assessments used for inclusion criteria and baseline severity evaluation in atopic dermatitis clinical trials: a systematic review. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017 , 31, 1890-1899	4.6	8
53	Dupilumab-Associated Ocular Surface Disease: Clinical Characteristics, Treatment, and Follow-Up. <i>Cornea</i> , 2021 , 40, 584-589	3.1	8
52	Management of inadequate response and adverse effects to dupilumab in atopic dermatitis. <i>Journal of the American Academy of Dermatology</i> , 2021 ,	4.5	8
51	Integrated Safety Analysis of Abrocitinib for the Treatment of Moderate-to-Severe Atopic Dermatitis From the Phase II and Phase III Clinical Trial Program. <i>American Journal of Clinical Dermatology</i> , 2021 , 22, 693-707	7.1	8
50	Understanding the cost of dermatologic care: A survey study of dermatology providers, residents, and patients. <i>Journal of the American Academy of Dermatology</i> , 2017 , 76, 609-617	4.5	7
49	Isoradiotopic response of lichen planus after radiotherapy of the breast. <i>JAAD Case Reports</i> , 2017 , 3, 246-249	1.4	7
48	Conjunctivitis in adult patients with moderate-to-severe atopic dermatitis: results from five tralokinumab clinical trials. <i>British Journal of Dermatology</i> , 2021 ,	4	7
47	Qualitative Assessment of Adult Patients' Perception of Atopic Dermatitis Using Natural Language Processing Analysis in a Cross-Sectional Study. <i>Dermatology and Therapy</i> , 2020 , 10, 297-305	4	7
46	The Rise in Atopic Dermatitis in Young Children: What Is the Explanation?. <i>JAMA Network Open</i> , 2018 , 1, e184205	10.4	7
45	Efficacy and Safety of Upadacitinib in Patients With Moderate to Severe Atopic Dermatitis: Analysis of Follow-up Data From the Measure Up 1 and Measure Up 2 Randomized Clinical Trials.. <i>JAMA Dermatology</i> , 2022 ,	5.1	7
44	Cutaneous responses to vaccinia in individuals with previous smallpox vaccination. <i>Journal of the American Academy of Dermatology</i> , 2007 , 57, 442-4	4.5	6
43	Development and Content Validation of Pruritus and Symptoms Assessment for Atopic Dermatitis (PSAAD) in Adolescents and Adults with Moderate-to-Severe AD. <i>Dermatology and Therapy</i> , 2021 , 11, 221-233	4	6
42	Direct and Indirect Effects of Crisaborole Ointment on Quality of Life in Patients with Atopic Dermatitis: A Mediation Analysis. <i>Acta Dermato-Venereologica</i> , 2019 , 99, 756-761	2.2	5
41	Patient-reported outcomes of adalimumab, phototherapy, and placebo in the Vascular Inflammation in Psoriasis Trial: A randomized controlled study. <i>Journal of the American Academy of Dermatology</i> , 2019 , 81, 923-930	4.5	5

40	Effect of Dupilumab on Laboratory Parameters in Adolescents with Atopic Dermatitis: Results from a Randomized, Placebo-Controlled, Phase 3 Clinical Trial. <i>American Journal of Clinical Dermatology</i> , 2021 , 22, 243-255	7.1	5
39	Insights into adult atopic dermatitis heterogeneity derived from circulating biomarker profiling in patients with moderate-to-severe disease. <i>Experimental Dermatology</i> , 2021 , 30, 1650-1661	4	5
38	Therapeutic New Era for Atopic Dermatitis: Part 2. Small Molecules. <i>Annals of Dermatology</i> , 2021 , 33, 101-107	0.4	5
37	Therapeutic New Era for Atopic Dermatitis: Part 1. Biologics. <i>Annals of Dermatology</i> , 2021 , 33, 1-10	0.4	5
36	Atopic dermatitis: emerging therapies. <i>Seminars in Cutaneous Medicine and Surgery</i> , 2017 , 36, 124-130	1.4	4
35	Chronic Hand Eczema Guidelines From an Expert Panel of the International Eczema Council. <i>Dermatitis</i> , 2021 , 32, 319-326	2.6	4
34	Recommended core outcome instruments for health-related quality of life, long-term control and itch intensity in atopic eczema trials: results of the HOME VII consensus meeting. <i>British Journal of Dermatology</i> , 2020 , 185, 139	4	4
33	Synergistic induction of IL-23 by TNF α /IL-17A, and EGF in keratinocytes. <i>Cytokine</i> , 2021 , 138, 155357	4	4
32	Clearing up misunderstandings around core outcomes for atopic dermatitis. <i>British Journal of Dermatology</i> , 2015 , 173, 623-4; discussion 624-5	4	3
31	Are epidermal defects the key initiating factors in the development of atopic dermatitis?. <i>British Journal of Dermatology</i> , 2010 , 163, 1147-8	4	3
30	Kotatsu-induced erythema ab igne. <i>Anais Brasileiros De Dermatologia</i> , 2019 , 94, 253-254	1.6	3
29	Expert Perspectives on Key Parameters that Impact Interpretation of Randomized Clinical Trials in Moderate-to-Severe Atopic Dermatitis. <i>American Journal of Clinical Dermatology</i> , 2021 , 1	7.1	3
28	Reply to: "Conclusions about atopic dermatitis persistence might be premature". <i>Journal of the American Academy of Dermatology</i> , 2017 , 76, e179	4.5	2
27	Validation of a Parent-Reported Diagnostic Instrument in a U.S. Referral Population: The Childhood Eczema Questionnaire. <i>Pediatric Dermatology</i> , 2017 , 34, 398-401	1.9	2
26	Acitretin therapy for Galli-Galli disease. <i>JAAD Case Reports</i> , 2020 , 6, 457-461	1.4	2
25	Correlation of atopic dermatitis with measurement tools in Korean patients: A retrospective study. <i>Indian Journal of Dermatology, Venereology and Leprology</i> , 2020 , 86, 738-740	0.8	2
24	Emerging Systemic Therapeutic Biologics and Small Molecules for Atopic Dermatitis: How to Decide Which Treatment Is Right for Your Patients. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021 , 9, 1449-1460	5.4	2
23	Definition of Clinically Meaningful Within-Patient Changes in POEM and CDLQI in Children 6 to 11 Years of Age with Severe Atopic Dermatitis. <i>Dermatology and Therapy</i> , 2021 , 11, 1415-1422	4	2

22	Development and content validity of new patient-reported outcome questionnaires to assess the signs and symptoms and impact of atopic dermatitis: the Atopic Dermatitis Symptom Scale (ADerm-SS) and the Atopic Dermatitis Impact Scale (ADerm-IS). <i>Current Medical Research and Opinion</i> , 2019 , 35, 1139-1148	2.5	2
21	Inverse Correlation of TRIM32 and Protein Kinase C β In T Helper Type 2-Biased Inflammation. <i>Journal of Investigative Dermatology</i> , 2021 , 141, 1297-1307.e3	4.3	2
20	Dupilumab reduces absenteeism in patients with moderate to severe atopic dermatitis: Pooled results from the LIBERTY AD SOLO clinical trials. <i>Journal of the American Academy of Dermatology</i> , 2020 , 83, 1499-1501	4.5	1
19	Dupilumab with Topical Corticosteroids Provides Rapid and Sustained Improvement in Adults with Moderate-to-Severe Atopic Dermatitis Across Anatomic Regions Over 52 Weeks. <i>Dermatology and Therapy</i> , 2021 , 12, 223	4	1
18	Clinical Tailoring of Baricitinib 2 mg in Atopic Dermatitis: Baseline Body Surface Area and Rapid Onset of Action Identifies Response at Week 16. <i>Dermatology and Therapy</i> , 2021 , 1	4	1
17	A survey in uncharted territory: A collaborative study to explore the approach to atopic dermatitis patient management in allopathy and naturopathy. <i>Pediatric Dermatology</i> , 2020 , 37, 109-114	1.9	1
16	The Effects of Common Over-the-Counter Moisturizers on Skin Barrier Function: A Randomized, Observer-Blind, Within-Patient, Controlled Study. <i>Dermatitis</i> , 2020 , 31, 309-315	2.6	1
15	Validation of a novel patient-operated device for measuring skin barrier function in atopic dermatitis. <i>Skin Research and Technology</i> , 2021 , 27, 824-830	1.9	1
14	Measurement properties of patient-reported outcome measures for eczema control: a systematic review. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021 , 35, 1987-1993	4.6	1
13	The atopic dermatitis spectrum disorder. Recognizing the clinical heterogeneity in patients with atopic related skin conditions in order to improve therapeutic decision-making and outcomes: an expert panel consensus statement. <i>Journal of Dermatological Treatment</i> , 2021 , 1-3	2.8	1
12	Good Practice Intervention for Clinical Assessment and Diagnosis of Atopic Dermatitis: Findings from the Atopic Dermatitis Quality of Care Initiative. <i>Dermatologic Therapy</i> , 2021 , e15259	2.2	1
11	Response to "Comment on: When does atopic dermatitis warrant systemic therapy? Recommendations from an expert panel of the International Eczema Council". <i>Journal of the American Academy of Dermatology</i> , 2018 , 79, e25-e26	4.5	0
10	Dupilumab Demonstrates Rapid and Consistent Improvement in Extent and Signs of Atopic Dermatitis Across All Anatomical Regions in Pediatric Patients 6 Years of Age and Older. <i>Dermatology and Therapy</i> , 2021 , 11, 1643-1656	4	0
9	International observational atopic dermatitis cohort to follow natural history and treatment course: TARGET-DERM AD study design and rationale. <i>BMJ Open</i> , 2020 , 10, e039928	3	0
8	Initial validation of the product of the signs global assessment and body surface area in atopic dermatitis. <i>Journal of the American Academy of Dermatology</i> , 2021 , 84, 283-289	4.5	0
7	Dupilumab significantly improves sleep outcomes in adult patients with atopic dermatitis: results from five randomized clinical trials. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021 , 35, e130-e133	4.6	0
6	Reply to: "Heterogeneity of data included in meta-analysis on persistence of atopic dermatitis alters interpretation". <i>Journal of the American Academy of Dermatology</i> , 2017 , 76, e183-e184	4.5	
5	Initial validation of the Burden of Disease in Atopic Eczema instrument, a quality-of-life measure for adult atopic dermatitis. <i>British Journal of Dermatology</i> , 2018 , 178, 1211-1212	4	

4 The Primary Prevention of Atopic Dermatitis **2014**, 127-135

3 Consistency of Response to Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis Over 1 Year.. *Dermatology and Therapy*, **2022**, 12, 9-13 4

2 Management of Cutaneous T-Cell Lymphoma/Mycosis Fungoides Occurring in the Setting of Solid Organ Transplantation: Report of 2 Cases. *Clinical Lymphoma, Myeloma and Leukemia*, **2020**, 20, e39-e42²

1 Low-dose methotrexate in dermatology: the utility of serological monitoring in a real-world cohort. *Journal of Dermatological Treatment*, **2021**, 1-7 2.8